Prescription medicine
Dichlorphenamide Brand names: Keveyis, Ormalvi
Dichlorphenamide (Keveyis) is a prescription medicine with an FDA approval on record since 1958. FDA's NDC Directory lists it from 3 generic labelers.
- Generic listed
Check it at the source: the dichlorphenamide FDA label on DailyMed (effective March 4, 2026, Xeris Pharmaceuticals, Inc.); the NDA 11366 record on Drugs@FDA; every dichlorphenamide label on DailyMed.
Highlights of the record
FDA label of March 4, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageKEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Forms and strengths
- 50 mg
Tablet.
On the market
- Earliest approval on file
- July 22, 1958 Keveyis, Xeris; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 2 first December 29, 2022; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 4 of which 3 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,639 through July 30, 2026
What is dichlorphenamide used for?
From the label: indications and usageKEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants
FDA pharmacologic class: Carbonic Anhydrase Inhibitor.
Source: FDA drug label (Keveyis), Xeris Pharmaceuticals, Inc., effective March 4, 2026 (SPL set d30a87b9-90fb-35b2-e053-2995a90aea2c), via openFDA; the full label on DailyMed
Is there a generic for dichlorphenamide (Keveyis)?
The FDA approved the first generic dichlorphenamide on December 29, 2022. 2 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists dichlorphenamide from 3 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1958 earliest approval on file
- 2022 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the dichlorphenamide label say about other medicines?
The dichlorphenamide label names 5 other medicines in its interaction, contraindication or warning sections. The labels of 13 other medicines name dichlorphenamide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | contraindications | CONTRAINDICATIONS KEVEYIS is contraindicated in the following circumstances: Hypersensitivity to dichlorphenamide or other sulfonamides [see Warnings and Precautions (5.1) ] Concomitant use of KEVEYIS and high dose aspirin [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] Severe pulmonary disease … |
| Famotidine | drug interactions | Use of KEVEYIS with drugs that are sensitive to OAT1 inhibition (e.g., methotrexate, famotidine, oseltamivir) is not recommended [see Clinical Pharmacology (12.3) ]. |
| Methotrexate | drug interactions | Use of KEVEYIS with drugs that are sensitive to OAT1 inhibition (e.g., methotrexate, famotidine, oseltamivir) is not recommended [see Clinical Pharmacology (12.3) ]. |
| Oseltamivir | drug interactions | Use of KEVEYIS with drugs that are sensitive to OAT1 inhibition (e.g., methotrexate, famotidine, oseltamivir) is not recommended [see Clinical Pharmacology (12.3) ]. |
| Theophylline | drug interactions | Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ]. |
Other labels that name dichlorphenamide
Source: FDA drug label (Keveyis), Xeris Pharmaceuticals, Inc., effective March 4, 2026 (SPL set d30a87b9-90fb-35b2-e053-2995a90aea2c), via openFDA; the full label on DailyMed
What do FAERS reports show for dichlorphenamide?
The FDA Adverse Event Reporting System holds 1,639 reports that list dichlorphenamide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 13 are coded as a death and 247 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other carbonic anhydrase inhibitors
- the pharmacologic class, with prices and generics
- Dichlorphenamide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other